Jaguar Health Inc (JAGX) Sees Large Drop in Short Interest
Jaguar Health Inc (NASDAQ:JAGX) was the recipient of a significant decrease in short interest during the month of March. As of March 29th, there was short interest totalling 309,546 shares, a decrease of 56.2% from the March 15th total of 707,275 shares. Based on an average daily trading volume, of 26,815,240 shares, the short-interest ratio is currently 0.0 days. Currently, 0.8% of the shares of the company are sold short.
Separately, ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a research report on Friday, April 5th.
Shares of NASDAQ JAGX opened at $0.22 on Tuesday. Jaguar Health has a 52 week low of $0.12 and a 52 week high of $3.20. The company has a quick ratio of 0.31, a current ratio of 0.46 and a debt-to-equity ratio of 1.03.
Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.
See Also: Quiet Period Expirations
Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.